Clinical characteristics and outcome of CLL/SLL patients with renal involvement in the era of targeted drugs
Abstract
Background Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) is a clonal mature B-cell neoplasm with rare extranodal organ renal involvement. Objectives To summarize the clinical and pathological characteristics of biopsy-confirmed CLL/SLL-associated renal lesions and evaluate the efficacy of targeted combination therapy. Design Retrospective multicenter observational study. Methods Eleven patients with CLL/SLL-associated nephropathy were enrolled from January 2017 to October 2024 across three Chinese centers. As of December 31, 2025, data were collected through electronic medical records and telephone follow-up. Results The median age was 58 (range 40–72) years. Among tested patients, 88.9% (8/9) exhibited IGHV mutation and 62.5% (5/8) were CLL-IPI low-risk, and no TP53 mutations were detected. The median time from CLL diagnosis to renal biopsy was 40.7 months (range: 0.2–58 months). Biopsy indictions included proteinuria (90.9%, 10/11), hematuria (54.5%, 6/11), renal dysfunction (54.5%, 6/11), and nephrotic syndrome (9.1%, 1/11). Main pathologies were tumor cell interstitial infiltration (45.5%, 5/11), membranoproliferative glomerulonephritis (27.3%, 3/11), membranous nephropathy (18.2%, 2/11), and C3 glomerulonephritis (9.1%, 1/11). Concomitant monoclonal gammopathy and cryoglobulinemia were observed in 27.3% and 18.2%, respectively. Nine patients received BTKi -based therapy. The best overall response rate (ORR) for CLL/SLL was 100%, with a CR rate of 72.7%. According to KDIGO 2021 guidelines, the renal best ORR was 100%, with a CR rate of 36.4%. Four patients achieved CR in both CLL and renal assessments. As of December 31, 2025, the median follow-up was 70.1 months and median PFS was not reached. Grade ≥3 hematologic toxicities included neutropenia (27.3%) and thrombocytopenia (18.2%). Common non-hematologic adverse events were COVID-19 (27.3%), bleeding (18.2%), and gastrointestinal symptoms (18.2%), all of grade 1-2. Conclusions CLL/SLL with renal involvement is associated with a favorable IGHV-mutated profile. Interstitial infiltration and membranoproliferative glomerulonephritis are the predominant renal pathologies. BTKi-based regimens were associated with favorable hematologic and renal outcomes in this small cohort.
Related
- Clinical Characteristics of Patients with Diabetes and Pulmonary Tuberculosis with Additional Extrapulmonary Involvement: A Retrospective Comparative Analysis.
- Clinical Characteristics and Factors Associated with Severe Disease in 64 Patients with Targeted Next-Generation Sequencing-Confirmed Chlamydia Psittaci Pneumonia: A Single-Centre Retrospective Study in Ningxia, China
- Echocardiographic characteristics and clinical features of cardiac involvement in Behçet’s disease: a retrospective single-center case series
- Clinical, immunological, and radiological characteristics of pulmonary involvement in childhood-onset primary Sjögren’s syndrome: a single-center retrospective study
- Clinical characteristics, risk factors, and outcome of Enterococcal bacteraemia: Assessment of the DENOVA score in a diverse patient cohort
BibTeX
@article{gao2026clinical,
title = {{Clinical characteristics and outcome of CLL/SLL patients with renal involvement in the era of targeted drugs}},
author = {Ling Gao and Minjie Yu and Lixia Sheng and Zhen Wang and Bo Zhang and Xiaoqian Liu and Tonglu Qiu and Wei Zhang and Luomengjia Dai and Ziyuan Zhou and Lei Fan and Jianyong Li and Huayuan Zhu},
journal = {Therapeutic Advances in Hematology},
year = {2026},
month = oct,
doi = {10.1177/20406207261501030},
url = {https://doi.org/10.1177/20406207261501030},
note = {CC BY},
}
RIS
TY - JOUR
TI - Clinical characteristics and outcome of CLL/SLL patients with renal involvement in the era of targeted drugs
AU - Ling Gao
AU - Minjie Yu
AU - Lixia Sheng
AU - Zhen Wang
AU - Bo Zhang
AU - Xiaoqian Liu
AU - Tonglu Qiu
AU - Wei Zhang
AU - Luomengjia Dai
AU - Ziyuan Zhou
AU - Lei Fan
AU - Jianyong Li
AU - Huayuan Zhu
PY - 2026
DA - 2026/10/24
JO - Therapeutic Advances in Hematology
DO - 10.1177/20406207261501030
UR - https://doi.org/10.1177/20406207261501030
AB - Background Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) is a clonal mature B-cell neoplasm with rare extranodal organ renal involvement. Objectives To summarize the clinical and pathological characteristics of biopsy-confirmed CLL/SLL-associated renal lesions and evaluate the efficacy of targeted combination therapy. Design Retrospective multicenter observational study. Methods Eleven patients with CLL/SLL-associated nephropathy were enrolled from January 2017 to October 2024 across three Chinese centers. As of December 31, 2025, data were collected through electronic medical records and telephone follow-up. Results The median age was 58 (range 40–72) years. Among tested patients, 88.9% (8/9) exhibited IGHV mutation and 62.5% (5/8) were CLL-IPI low-risk, and no TP53 mutations were detected. The median time from CLL diagnosis to renal biopsy was 40.7 months (range: 0.2–58 months). Biopsy indictions included proteinuria (90.9%, 10/11), hematuria (54.5%, 6/11), renal dysfunction (54.5%, 6/11), and nephrotic syndrome (9.1%, 1/11). Main pathologies were tumor cell interstitial infiltration (45.5%, 5/11), membranoproliferative glomerulonephritis (27.3%, 3/11), membranous nephropathy (18.2%, 2/11), and C3 glomerulonephritis (9.1%, 1/11). Concomitant monoclonal gammopathy and cryoglobulinemia were observed in 27.3% and 18.2%, respectively. Nine patients received BTKi -based therapy. The best overall response rate (ORR) for CLL/SLL was 100%, with a CR rate of 72.7%. According to KDIGO 2021 guidelines, the renal best ORR was 100%, with a CR rate of 36.4%. Four patients achieved CR in both CLL and renal assessments. As of December 31, 2025, the median follow-up was 70.1 months and median PFS was not reached. Grade ≥3 hematologic toxicities included neutropenia (27.3%) and thrombocytopenia (18.2%). Common non-hematologic adverse events were COVID-19 (27.3%), bleeding (18.2%), and gastrointestinal symptoms (18.2%), all of grade 1-2. Conclusions CLL/SLL with renal involvement is associated with a favorable IGHV-mutated profile. Interstitial infiltration and membranoproliferative glomerulonephritis are the predominant renal pathologies. BTKi-based regimens were associated with favorable hematologic and renal outcomes in this small cohort.
SN - 2040-6215
SN - 2040-6207
ER -